Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avinger, Inc. stock logo
AVGR
Avinger
$0.47
$0.47
$0.36
$1.93
$1.57M1.291.46 million shsN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
$2.69
-1.8%
$3.97
$2.61
$16.50
$1.49M0.6665,255 shs40,267 shs
LogicMark, Inc. stock logo
LGMK
LogicMark
$0.00
-19.2%
$0.00
$0.00
$7.63
$2.42M1.4980.84 million shs21.64 million shs
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$0.02
-80.6%
$0.11
$0.00
$4.57
$326K0.25555,725 shs7,846 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avinger, Inc. stock logo
AVGR
Avinger
0.00%0.00%0.00%0.00%-62.68%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-1.82%+0.75%-22.61%-33.58%-81.08%
LogicMark, Inc. stock logo
LGMK
LogicMark
-19.23%+27.27%+40.00%-69.12%-99.94%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-80.63%+1.97%-88.93%-90.31%-99.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/AN/AN/AN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
0.7671 of 5 stars
0.05.00.00.00.00.01.3
LogicMark, Inc. stock logo
LGMK
LogicMark
0.7902 of 5 stars
0.03.00.00.03.30.00.6
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avinger, Inc. stock logo
AVGR
Avinger
0.00
N/AN/AN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
0.00
N/AN/AN/A
LogicMark, Inc. stock logo
LGMK
LogicMark
0.00
N/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.21N/AN/A($4.53) per share-0.10
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/AN/AN/AN/A$8.39 per shareN/A
LogicMark, Inc. stock logo
LGMK
LogicMark
$9.88M0.24N/AN/A$148.65 per share0.00
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
$7.68M0.04N/AN/A($6.91) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$4.11MN/A0.00N/AN/AN/A-130.21%-119.39%8/8/2025 (Estimated)
LogicMark, Inc. stock logo
LGMK
LogicMark
-$14.55M-$223.50N/AN/A-141.96%-124.91%-92.05%8/12/2025 (Estimated)
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
-$50.08MN/A0.00N/A-563.16%N/A-174.06%10/6/2025 (Estimated)

Latest TTOO, LGMK, BBLG, and AVGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
LogicMark, Inc. stock logo
LGMK
LogicMark
-$0.03N/AN/AN/A$2.35 millionN/A
8/8/2025N/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$1.93N/AN/AN/AN/AN/A
5/15/2025Q1 2025
LogicMark, Inc. stock logo
LGMK
LogicMark
-$0.03-$0.12-$0.09-$0.12$2.23 million$2.59 million
5/12/2025Q1 2025
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
-$2.88-$1.92+$0.96-$0.32N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/AN/AN/AN/AN/A
LogicMark, Inc. stock logo
LGMK
LogicMark
N/AN/AN/AN/AN/A
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/A
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
N/A
12.60
12.60
LogicMark, Inc. stock logo
LGMK
LogicMark
N/A
3.73
3.29
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
N/A
0.40
0.24

Institutional Ownership

CompanyInstitutional Ownership
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
34.30%
LogicMark, Inc. stock logo
LGMK
LogicMark
7.88%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
23.18%

Insider Ownership

CompanyInsider Ownership
Avinger, Inc. stock logo
AVGR
Avinger
42.80%
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
7.50%
LogicMark, Inc. stock logo
LGMK
LogicMark
2.17%
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
0.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avinger, Inc. stock logo
AVGR
Avinger
703.31 million1.89 millionNot Optionable
Bone Biologics Corp. stock logo
BBLG
Bone Biologics
2550,000504,000Not Optionable
LogicMark, Inc. stock logo
LGMK
LogicMark
20576.31 million2.65 millionNo Data
T2 Biosystems, Inc. stock logo
TTOO
T2 Biosystems
18021.04 million21.04 millionOptionable

Recent News About These Companies

Short Interest in T2 Biosystems, Inc. (NASDAQ:TTOO) Expands By 1,146.7%
TTOO T2 Biosystems, Inc. - Seeking Alpha
T2 Biosystems Inc. (TTOO) After Hours Quote
T2 Biosystems initiates major layoffs, seeks asset sale
T2 Biosystems to be delisted from Nasdaq
T2 Biosystems reports preliminary Q4 revenue $2.3M
T2 Biosystems announces sale of four T2Dx Intruments to European distributor
T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avinger stock logo

Avinger NASDAQ:AVGR

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.

Bone Biologics stock logo

Bone Biologics NASDAQ:BBLG

$2.69 -0.05 (-1.82%)
Closing price 08/5/2025 04:00 PM Eastern
Extended Trading
$3.89 +1.20 (+44.61%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

LogicMark stock logo

LogicMark NASDAQ:LGMK

$0.0042 0.00 (-19.23%)
As of 08/5/2025 03:55 PM Eastern

LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company's devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one's health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.

T2 Biosystems stock logo

T2 Biosystems NASDAQ:TTOO

$0.02 -0.06 (-80.63%)
As of 08/5/2025 11:22 AM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.